Most Read Articles
Roshini Claire Anthony, 4 days ago

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Weight-loss surgery helps resolve nonalcoholic steatohepatitis

26 Jun 2020

Bariatric surgery may lead to the resolution of nonalcoholic steatohepatitis (NASH) with a sustained reduction in fibrosis over 5 years, as shown in a study.

Researchers followed for 5 years a total of 180 severely obese patients (mean age, 46.7 years; median fibrosis score, 2) with biopsy-proven NASH who underwent bariatric surgery (66.1 percent had gastric bypass). Three patients died from non-liver-related causes: two from surgical complications within the first month after surgery and one from cardiac dysfunction at the 4-year follow-up.

Liver biopsies were obtained from 125 of 169 patients (76 percent) in the first year of follow-up and from 64 of 94 patients (68 percent) at the fifth year. Histological evaluation was not available in some patients mainly because of biopsy refusal.

At 5 years after weight-loss surgery, 84 percent of patients achieved the primary endpoint of resolution of NASH without worsening of fibrosis. Moreover, fibrosis decreased from baseline in 70.2 percent of patients. It disappeared in biopsy samples from 56 percent of all patients, as well as in samples from 45.5 percent of those with baseline bridging fibrosis.

NASH persistence was predicted by a lack of fibrosis reduction and less weight loss (mean reduction in body mass index, –6.3 vs –13.4 kg/m2 in patients with persistent vs resolved NASH, respectively; p=0.017).

NASH resolution was observed at 1 year post-bariatric surgery in biopsies from 84 percent of patients, with no significant recurrence between 1 and 5 years (p=0.17). Finally, reductions in fibrosis started to occur by 1 year and continued until 5 years (p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.